| Name | Title | Contact Details |
|---|
RNL BioStar Inc. is a Germantown, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Centrillion Biosciences is a leading genomic and bioinformatics solution provider.
Modern Meadow was founded on the belief that customers should not have to choose between performance and sustainability. Additionally, we believe that people should not have to choose between a career that helps them achieve their personal goals and a career with purpose. Achieving both personal and professional goals with purpose is possible at Modern Meadow, and we invite qualified professionals to apply for positions of interest. At the intersection of biotechnology and material science, Modern Meadow designs materials solutions for the way we want the world to perform. We are pioneers of biofabrication, building with biology. This enbables us to harness unique properties of proteins to move the world away from petrochemical and animal-derived inputs, leading a shift to the bioeconomy. Modern Meadow Biofabricated Materials offer the world a new way forward. By introducing a more effective, more responsible, and readily available supply, we are shifting demand away from extractive practices and toward a sustainable bioeconomy. Our team is engaged in exciting work to enable us all to move beyond sustainability to real world impact. Our philosophy and sustainability principles help us stay focused on the most critical environmental issues and challenge us to design our products and systems in the most sustainable manner. But we cannot build a bioeconomy alone. We are partnering with companies, developing bio-based supply chains, and speaking with businesses looking to design for sustainability from the start. Together we can create new coalitions to build out the environmentally conscious alternatives our planet desperately needs.
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company`s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib has shown antitumor activity and durable responses among kinase-naïve and pre-treated patients, and is expected to enter a registrational study in the second half of 2019. Turning Point`s kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to overcome treatment resistance common in other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
Sage Rutty and Co is a Rochester, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.